Privi Speciality Chemicals Limited (PRIVISCL) Q2 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Privi Speciality Chemicals is a single-segment aroma chemicals maker serving the fragrance and FMCG industries, and its Q2 print lands against an all-time-high base of Rs. 678.82 Cr revenue and a 26.83% EBITDA margin from Q2 FY26. The two things to watch are whether EBITDA margins hold the guided 24-26% band amid alpha-pinene inflation of 70-80% in five months, and whether the Phase-1 54,000 MT capacity was commissioned in September 2026 as last committed.

Privi Speciality Chemicals Limited Q2 Results Date and Time

The board will meet Thursday, October 29, 2026, to approve unaudited standalone and consolidated results for Q2/H1 ended September 30, 2026, and consider the first interim dividend for FY 2026-27. The trading window for designated persons has been closed since October 1, 2026.

The earnings call is scheduled for Friday, October 30, 2026, at 16:00 hrs IST for the quarter and half year ended September 30, 2026. Pre-registration is required, and the transcript will be posted on the company website within five working days.

What to expect from Privi Speciality Chemicals Limited's Q2 FY27 results

The quarter's central test is margin: Q2 FY27 laps the all-time-high Q2 FY26 base of Rs. 678.82 Cr revenue and 26.83% EBITDA margin, while Brent crude rose from about $90/bbl at end-July to a $105-107 exit through September, repricing the 15-18% of purchases that are crude-based, and alpha-pinene is already up 70-80% in five months with GTO at historic highs. Two buffers temper the cost read: the company runs a 3-month stock plus 2-3 month pipeline inventory policy, so Q2 consumption likely drew on lower-cost stock with the inflation landing in the October-December contract-renewal window, and the weaker rupee (spot at 95.72-96.61 in recent fortnights per RBI/FBIL data dated October 16, 2026) supports reported revenue for a net exporter while partially offsetting the 70% import component of raw materials. End-demand is a tailwind: Givaudan printed Q3 2026 like-for-like sales growth of 8.6% with its fragrance division at +13.5%, and India FMCG value growth hit a six-quarter high of 8.6% YoY in Q2 FY27 per Bizom data, consistent with management's 'healthy demand across domestic and international markets' framing. The guided 24-26% EBITDA-margin band — near-term 'almost similar' to Q1 FY27's 24.58%, which included about 42 bps of uncorrected fire impact — is the line to hold, against the conservative 20-22% 'VUCA world' framing if pass-through slips. On growth, the 20% CAGR path (implying about Rs. 3,099.50 Cr for FY27) and the Rs 5,000 Cr revenue / Rs 1,000 Cr+ EBITDA FY29-30 ambition remain intact, with FY27 growth back-ended towards H2 given Phase-1 commissioning timing; the call will also cover the October 27, 2026 shareholder meeting on the Privi Fine Sciences amalgamation and PRIGIV JV progress toward approximately Rs. 130 Cr FY27 revenue.

Key Things To Watch

Performance vs Guidance Tracking: Guidance scorecard to check on the Q2 FY27 call:

• Revenue — Rs 5,000 Cr by FY29-30 / next 3-4 yrs — FY26 Rs. 2,582.92 Cr, about 1.94x to target
• EBITDA — Rs 1,000 Cr+ by FY29-30 / next 3-4 yrs — FY26 Rs. 665.45 Cr
• EBITDA margin — 24-26% / ~25% open-ended — Q1 FY27 at 24.58%
• Growth — 20% CAGR open-ended — implied FY27 about Rs. 3,099.50 Cr
• Phase 1 capacity — 54,000 MT by September 2026 — verify commissioning
• Phase 2 capacity — 66,000 MT by September 2027 — on track per Q1 FY27
• Capex — Rs 1,200 Cr over 2-3 years; Rs. 850-900 Cr over FY27-29
• PRIGIV revenue — approximately Rs. 130 Cr in FY27 — Q1 FY27 at Rs. 18 Cr
• Debt/EBITDA — below 2.5x open-ended guideline — 1.29x at Q1 FY27
• FY27 volume growth — about 7% vs 11-15% — divergent internal views
• Merger — NCLT order received; shareholder meeting October 27, 2026
• First interim dividend — consideration on October 29, 2026

Margins vs the all-time-high base and raw material pass-through

• Q2 FY27 laps Q2 FY26's record revenue of Rs. 678.82 Cr and 26.83% EBITDA margin; watch whether margins hold the 24-26% band or drift toward the conservative 20-22% VUCA framing
• Update on alpha-pinene (+70-80% in five months) and GTO at historic highs, and pass-through into the October-December contract renewals — the exact question deferred since Q2 FY26
• Whether the ~42 bps Q1 FY27 fire impact on EBITDA margin was corrected via receipt of the insurance claim

Phase 1 commissioning and H2-back-ended growth

• Confirm whether the 54,000 MT capacity was commercialized in September 2026 as last committed, with the 'calibrated ramp-up... progressively over the coming quarters' cadence
• Check whether management reiterates that FY27 growth is back-ended and where volume growth tracks within the 7% vs 11-15% internal divergence

Merger execution and PRIGIV ramp

• The shareholder meeting on the Privi Fine Sciences / Privi Biotechnologies amalgamation is October 27, 2026 — two days before the board meeting; watch for the NCLT final order and consolidation timing
• When the approximately Rs. 400 crores Privi Fine Sciences revenue and the additional ~6,000 MT post-merger capacity enter consolidated numbers
• PRIGIV progress toward approximately Rs. 130 Cr FY27 revenue from Rs. 18 Cr in Q1, plus the Rs. 50 Cr equity infusion and additional capex for Rs. 100+ Cr revenue potential

New molecule commissioning and balance sheet

• Updates on Silver Amber, Amber Silk, Privilege and Privitolide commissioning through FY27, and maltol/ethyl maltol/cyclopentanone progress toward June 2027 mechanical completion
• Net debt of Rs. 865 Cr at Q1 FY27 against the sub-2.5x debt/EBITDA guideline while funding Rs. 850-900 Cr of capex